ArticleExperimental and therapeutic medicine2012
CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study.
Article in Experimental and therapeutic medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The prognostic role of CD133 expression in patients with osteosarcoma.Clinical and experimental medicine · 2020Pooled it
- PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis.Cancer gene therapy · 2020Pooled it
- Cluster of differentiation 133 (CD133) and C-X-C chemokine receptor 4 (CXCR4) associated with the incidence of metastasis in osteosarcoma patients.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025Article
- The paradoxical role of stem cells in osteosarcoma: from pathogenesis to therapeutic breakthroughs.Frontiers in oncology · 2025Review
- Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma.International journal of biological sciences · 2025Article
- Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.International journal of molecular sciences · 2024Article
- Cellular and Genetic Background of Osteosarcoma.Current issues in molecular biology · 2023Review
- The Role of Tumor Microenvironment in Regulating the Plasticity of Osteosarcoma Cells.International journal of molecular sciences · 2022Review
- Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.International journal of molecular sciences · 2022Review
- Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Osteosarcoma Stem Cell Potent Gallium(III)-Polypyridyl Complexes Bearing Diflunisal.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.Annals of the New York Academy of Sciences · 2021Article
- The Clinical Impact of Cancer Stem Cells.The oncologist · 2020Review
- Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Review
- Effect of chemotherapy on cancer stem cells and tumor-associated macrophages in a prospective study of preoperative chemotherapy in soft tissue sarcoma.Journal of translational medicine · 2019Article
- Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.JCI insight · 2018Article
- Novel molecular insights and new therapeutic strategies in osteosarcoma.Cancer cell international · 2018Review
- Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.International journal of oncology · 2017Article
- Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying prognostic factors for osteosarcoma (OS) aids in the selection of patients who require more aggressive management. CD133 has been found to be a prognostic factor of certain tumor types. However, the association between CD133 expression and the prognosis of OS remains unknown. In this study, we analyzed the association of CD133 expression in OS with clinical factors and overall survival, and further investigated its potential role in metastasis in vitro. We found CD133 expression in 65.7% (46/70) of OS samples using immunohistochemistry, and it was positively correlated with lung metastasis analyzed by Chi-square test (P=0.002) and shorter overall survival time using the Kaplan-Meier method compared by log-rank test (P=0.000). Multivariate analysis showed that CD133 expression was an independent prognostic factor of patients with OS. To test for direct participation of CD133, we separated CD133(+) and CD133(-) cells in the MG63 cell line using magnetic-activated cell sorting and found that CD133(+) cells were more active in migration by scratch wound-healing assay and invasion by Matrigel invasion assay compared with CD133(-) cells. Elevated mRNA expression of the stemness gene octamer-binding transcription factor 4 (Oct-4) and NANOG, and the metastasis-related receptor C-X-C chemokine receptor type 4 (CXCR4) were also found in CD133(+) cells by reverse transcription-polymerase chain reaction. Thus, expression of CD133 was correlated with lung metastasis and poor prognosis in OS patients. CD133(+) cells may be a type of cancer stem cell with high expression of self-renewal capacity and metastasis-related genes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.